RELAPSING MULTIPLE SCLEROSIS (RMS)
Clinical trials for RELAPSING MULTIPLE SCLEROSIS (RMS) explained in plain language.
Never miss a new study
Get alerted when new RELAPSING MULTIPLE SCLEROSIS (RMS) trials appear
Sign up with your email to follow new studies for RELAPSING MULTIPLE SCLEROSIS (RMS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New MS drug shows promise in Long-Term trial
Disease control OngoingThis study looks at the long-term safety and effectiveness of ublituximab, a drug for relapsing multiple sclerosis (RMS). About 1,100 people who completed earlier studies will continue treatment. The main goal is to see how well the drug reduces relapse rates over time.
Matched conditions: RELAPSING MULTIPLE SCLEROSIS (RMS)
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 04:26 UTC
-
New dosing strategy for MS drug ofatumumab under study
Disease control OngoingThis study tests a new maintenance dosing schedule of the drug ofatumumab in people with relapsing multiple sclerosis (RMS). The goal is to see if the new schedule works as well as the approved one in terms of drug levels in the blood, safety, and tolerability. About 196 adults a…
Matched conditions: RELAPSING MULTIPLE SCLEROSIS (RMS)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:02 UTC